Other News To Note
APP Pharmaceuticals Inc., of Schaumburg, ILL., and The Medicines Co. (MDCO), of Parsippany, N.J., settled litigation related to APP's abbreviated new drug application for a generic version of the anti-clotting drug Angiomax (bivalirudin for injection). MDCO licensed APP to begin selling APP's generic version of Angiomax in the U.S. on May 1, 2019, or earlier, in certain circumstances.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST